Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Qfitlia potentially requiring only six subcutaneous injections per year significantly reduces disease burden, eliminating the need for frequent intravenous injections associated with traditional factor treatment

  80% confidence

• Qfitlia approval marks a true transition to a new era of non-factor prophylactic treatment for hemophilia in China

  80% confidence

• These approvals underscore Sanofi's commitment to bringing significant innovations and improving the lives of people with rare diseases in China and worldwide

  80% confidence

• Qfitlia has the potential to make prophylaxis more accessible to people with hemophilia worldwide by offering effective bleeding protection and simplified administration

  80% confidence

• These approvals mark a new milestone in Sanofi's long-term commitment to China, reinforcing the company's ambition to bring transformative medicines across various therapeutic areas

  80% confidence

• This innovation offers people with hemophilia A or B, with or without inhibitors, a new therapeutic option by lowering antithrombin levels to restore coagulation balance

  80% confidence

• Cablivi addresses a critical unmet need in patients facing acquired thrombotic thrombocytopenic purpura

  80% confidence

• Qfitlia represents a potentially transformative advancement for the hemophilia community in China, evolving care from treating bleeds as they occur to a comprehensive preventive approach

  80% confidence

Data points we hold from this source